Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Inv. presentation
Immunovant, Inc. (IMVT) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
08/23/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/10/2023 8-K Quarterly results
Docs: "Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023"
03/27/2023 8-K Investor presentation
Docs: "Targeted Science, Tailored Solutions Corporate Presentation March 2023 Exhibit 99.1 Forward-looking Statements 2 This"
02/03/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022"
01/09/2023 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/04/2022 8-K Quarterly results
10/04/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among the Company and SVB Securities LLC",
"Opinion of Cooley LLP",
"Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock New York, October 4, 2022 - Immunovant, Inc. , a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of $6.00 per share. Investors who have agreed to purchase shares in the offering include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF Partners L.P., Commodore Capital, and an undisclosed healthcare specialist fund. Before deducting the underwriting discounts and commissions and offering expenses, the company expects to receive total gross proceeds of $75.0 million. The company intends to use the net proceeds f..."
09/28/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn",
"50 0 50 100 0 7 14 21 28 35 42 56"
09/07/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Immunovant Announces Plans to Study Batoclimab in Two New Indications Committed to",
"Immunovant Announces Two New Development Programs for Batoclimab"
08/19/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
03/30/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "The Private Securities Litigation Reform Act of 1995 and"
02/04/2022 8-K Quarterly results
01/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference"
01/05/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Phase 3 Development for Batoclimab in Myasthenia Gravis Corporate Update January 2022"
12/30/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022"
11/23/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
11/17/2021 8-K Investor presentation
Docs: "Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference",
"Stifel 2021 Virtual Healthcare Conference Investor Presentation November 17, 2021 For Investor Audiences Only Exhibit 99.2"
11/05/2021 8-K Quarterly results
Docs: "Immunovant Reports Financial Results for the Quarter Ended September 30, 2021 Company Ended the Quarter With Cash of Approximately $559 Million"
09/27/2021 8-K Investor presentation
Docs: "Immunovant to Participate in Roivant R&D Day 2021",
"For Investor Audiences Only Roivant"
09/15/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
Docs: "Immunovant Reports Financial Results for the Quarter Ended June 30, 2021"
08/02/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...
Docs: "SHARE PURCHASE AGREEMENT"
07/13/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
02/02/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Immunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020 Company Ended the Quarter With Cash of Approximately $444 Million"
09/18/2020 8-K Other Events
08/25/2020 8-K Quarterly results
08/21/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy